PHILADELPHIA, PA / ACCESSWIRE / June 2, 2021 / Kaskela Law LLC announces that it is investigating Immunovant, Inc. (Nasdaq: IMVT) on behalf of the Company's stockholders.
On June 1, 2021, shares of Immunovant's common stock declined $5.76 per share, or 38% in value, after the Company reported its financial and operational results for the Quarter and Fiscal Year ended March 31, 2021, and disclosed that its Chief Medical Officer ("CMO"), Rita Jain, M.D., had stepped down "to pursue another opportunity."
The investigation seeks to determine whether Immunovant and the company's executive officers and/or directors violated the securities laws in connection with statements made to investors, and whether Immunovant investors have been harmed as a result of such actions.
Immunovant investors are encouraged to contact Kaskela Law LLC at https://kaskelalaw.com/case/immunovant-inc/ for additional information about this investigation and their legal rights and options.
Kaskela Law LLC represents investors in securities fraud, corporate governance, and merger & acquisition litigation. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com. This notice may constitute attorney advertising in certain jurisdictions.
SOURCE: Kaskela Law LLC